Resultados de Búsqueda
There is uncertainty about the use of antimicrobial mouthwashes and nasal sprays used by healthcare workers to protect themselves when treating patients with suspected or confirmed COVID-19 infection.
Evidencias COVID-19
Cochrane - Revisión rápida
There is currently no evidence of the benefits and risks of healthcare workers using antimicrobial mouthwashes or nasal sprays to protect themselves when treating people with COVID-19. No completed studies were found for inclusion in this review. Three ongoing studies (including two RCTs) were identified, claiming to include almost 700 participants. The interventions included in these trials are povidone iodine, nitric oxide and GLS-1200 oral spray. Once these studies are completed, their ...
ver más ... 2020The use of selexipag has shown more risks than benefits in patients with pulmonary arterial hypertension.
Prescrire bilan. Towards better patient care: drugs to avoid
Prescrire International
The oral prostacyclin receptor agonist selexipag, authorised for pulmonary arterial hypertension, has been dropped from this year’s list.It was added to the list of drugs to avoid in 2018. It was removed in 2019 and it has not been put back on 2020 list, even though its harm-benefit balance is highly uncertain, and the risk that it hastens the death of certain patients during the first months of treatment has not been ruled out
ver más ... 2020The use of canaglifozin in type 2 diabetes presents an unfavorable benefit-harm balance
Prescrire bilan. Towards better patient care: drugs to avoid
Prescrire International
As of 2019, glucose-lowering drugs belonging to the gliflozin class (sodium-glucose co-transporter 2 inhibitors) have an unfavourable harm-benefit balance in type 2 diabetes. However, they did not include the gliflozins in their 2020 list of drugs to avoid, because dapagliflozin has been authorised for use in type 1 diabetes, and their analysis of its harm-benefit balance in this situation is in progress.
ver más ... 2020Treatment with type I interferon is recommended in COVID-19 patients as it is associated with positive clinical results in terms of mortality and discharge.
Evidencias COVID-19
IHCAI – DIME. Información seleccionada sobre intervenciones para el tratamiento de COVID-19
A systemic review and meta-analysis were performed to assess the role of Janus-kinase (JAK) inhibitors and type I interferons in COVID-19 patients, as they are potential antiviral candidates for COVID-19 patients. for its proven efficacy against diseases with excessive cytokine release and for its ability to promote viral shedding. We searched 733 studies, ultimately including four randomized and eleven non-randomized clinical trials.
ver más ... 2020Treatment with JAK inhibitors is recommended in patients with COVID- 19 since it is significantly associated with positive clinical results in terms of mortality, ICU admission and discharge
Evidencias COVID-19
IHCAI – DIME. Información seleccionada sobre intervenciones para el tratamiento de COVID-19
A systemic review and meta-analysis were performed to assess the role of Janus-kinase (JAK) inhibitors and type I interferons in COVID-19 patients, as they are potential antiviral candidates for COVID-19 patients. for its proven efficacy against diseases with excessive cytokine release and for its ability to promote viral shedding. We searched 733 studies, ultimately including four randomized and eleven non-randomized clinical trials.
ver más ... 2020